GlassScriptPhysician profile
Reshma C Katira
NPI 1700851607
$1,761.34
in general payments reported to CMS, 2019-2025
20 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $171 · 2021: $74.14 · 2022: $43.46 · 2023: $485 · 2024: $394 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.29 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $258.44 | 2023-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $208.37 | 2023-2025 | Izervay |
| Allergan, INC. | $173.67 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 | |
| Genentech USA, INC. | $111.41 | 2019-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $74.36 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $68.33 | 2025 | Iluvien |
| Amgen INC. | $64.94 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $56.44 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $45.69 | 2024-2025 | Xipere |
| Vyera Pharmaceuticals, LLC | $41.84 | 2021 | |
| Sun Pharmaceutical Industries INC. | $39.43 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $36.83 | 2024 | Xdemvy |
| Eyepoint US, INC. | $35.18 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $23.69 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $23.37 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $18.49 | 2024 | Imcivree |
| Shire North American Group INC | $15.20 | 2019 | |
| Omeros Corporation | $15.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Katira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.